Bringing the Oncology Community Together

Dr. Erba on Azacitidine and Gemtuzumab Ozogamicin

Harry Erba, MD, PhD
Published Online: Wednesday, January 23, 2013
Harry Erba, MD, PhD, professor of medicine and director, University of Alabama at Birmingham Hematologic Malignancy Program, discusses the results of a phase II study analyzing azacitidine and gemtuzumab ozogamicin as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 acute myeloid leukemia.

Data from the good risk cohort were presented at ASCO 2012. The results of the poor risk patients were presented at the 2012 American Society of Hematology Meeting. Of the 54 total poor risk patients that were treated, 35% achieved a complete remission or CRi. The study found median progression-free survival to be seven months and median overall survival six months.

In the entire study, between 30% and 50% of patients responded to the combination of azacitidine and gemtuzumab ozogamicin, Erba says, and that it remains unclear how patients would have responded to either agent as monotherapy or to intensive chemotherapy.

Related Articles
FDA Approves First-Line Ofatumumab for Fludarabine-Ineligble Patients With CLL
The FDA has approved ofatumumab plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia who are considered inappropriate for treatment with fludarabine therapy.
Epizyme Maintains Independence, Advances HMT-Inhibitor Platform
Epizyme, a Cambridge, Massachusetts-based biotech, opted for independence, with a successful IPO in 2013.
Hitting the Target: How Druker’s Persistence Helped Launch a New Mode of Attack
Take a prognosis of three years, multiply it by 10, and what do you get? A staggering improvement in the survival of patients with chronic myeloid leukemia (CML), and a crucial steppingstone on the road to the targeted treatment of cancer.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.